4 analysts have expressed a variety of opinions on Hims & Hers Health (NYSE:HIMS) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 1 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 1 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $49.5, a high estimate of $85.00, and a low estimate of $32.00. A 12.39% drop is evident in the current average compared to the previous average price target of $56.50.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Hims & Hers Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mark Mahaney | Evercore ISI Group | Announces | In-Line | $33.00 | - |
| Glen Santangelo | Barclays | Announces | Overweight | $48.00 | - |
| Allen Lutz | B of A Securities | Raises | Underperform | $32.00 | $28.00 |
| David Larsen | BTIG | Maintains | Buy | $85.00 | $85.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Hims & Hers Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hims & Hers Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
All You Need to Know About Hims & Hers Health
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Financial Milestones: Hims & Hers Health's Journey
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Hims & Hers Health's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 49.16%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Hims & Hers Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.76% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.77%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.92, Hims & Hers Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!